Bell v Tavistock Lawsuit: Rulings, Cass Review, and UK Policy

Bell v Tavistock was a UK judicial review brought by Keira Bell, a former patient of England’s only youth gender clinic, challenging whether children could lawfully consent to puberty-blocking drugs. The High Court ruled in her favor in December 2020, holding that under-16s were unlikely to be competent to consent, but the Court of Appeal overturned that ruling in September 2021 and restored clinical discretion to doctors. The UK Supreme Court refused to hear a further appeal in May 2022. Bell lost the legal argument, yet the concerns her case raised drove the Cass Review, the closure of the Tavistock’s gender service, and an indefinite ban on puberty blockers for gender dysphoria in minors.

Who Keira Bell Is

Bell was born female and began questioning her gender at around 14, after a childhood she has described as marked by parental abandonment, anxiety, depression, and confusion about her sexual orientation. At 15 she was referred to the Gender Identity Development Service (GIDS) at the Tavistock and Portman NHS Foundation Trust in London, the sole specialist provider of gender services for under-18s in England.¹ She received puberty blockers at 16, testosterone at 17, and a double mastectomy at 20.²

Around age 22 she stopped testosterone and began detransitioning. She has spoken publicly about lasting physical consequences: nerve damage from surgery, a permanently deepened voice, facial hair, atrophied genitals, and potential infertility. In her words, “there was nothing wrong with my body,” and the medical pathway had been a “temporary fix.”³²

The clinic itself did not prescribe the drugs. GIDS assessed patients and referred them to paediatric endocrinologists at University College London Hospitals or Leeds Teaching Hospitals, who wrote the prescriptions. The standard pathway ran from puberty blockers at roughly 12 to 15, cross-sex hormones at around 16, and surgery from 18. In 2019–2020 the service referred 161 people under 18 for puberty blockers.⁴

For patients under 16, the Trust relied on Gillick competence — the test from the 1985 House of Lords decision in Gillick v West Norfolk and Wisbech Area Health Authority, which holds that a child can consent to treatment if they have “sufficient understanding and intelligence” to grasp what is proposed.¹

The 2020 High Court Ruling

On 1 December 2020, a Divisional Court of Dame Victoria Sharp, Lord Justice Lewis, and Mrs Justice Lieven handed down judgment in R (Quincy Bell) and A v Tavistock and Portman NHS Foundation Trust [2020] EWHC 3274 (Admin).⁵

The judges said it was “highly unlikely” that a child aged 13 or under could ever be Gillick competent to consent to puberty blockers, and “very doubtful” that 14- and 15-year-olds could understand the long-term consequences.⁶ To be competent, they said, a child would need to understand and weigh the immediate physical and psychological effects, the fact that most patients who start blockers go on to cross-sex hormones, the link between hormones and surgery, potential loss of fertility, effects on sexual function and future relationships, unknown physical consequences, and the uncertain evidence base.⁷ The court described the treatment as “experimental.”⁵

The practical effect landed at once. NHS England amended its service specification so that patients under 16 seeking puberty blockers would need a court “best interests” order, and clinicians were told to consider court authorization even for 16- and 17-year-olds. New referrals for puberty blockers and cross-sex hormones for under-16s were suspended.⁷

The 2021 Court of Appeal Reversal

The Tavistock Trust, UCLH, and Leeds Teaching Hospitals appealed. On 17 September 2021 the Court of Appeal (Lord Burnett of Maldon, Sir Geoffrey Vos, and Lady Justice King) allowed the appeal and set aside the lower court’s declarations and guidance.⁸

The Court of Appeal held that the Divisional Court had improperly stepped into a fact-finding role, resolving contested expert evidence (much of it technically inadmissible) as though it were established fact. Judicial review, it said, was not the forum for settling clinical controversies. On the central legal point, the appeal court reaffirmed Gillick: it is for doctors, not judges, to assess whether an individual child has the maturity to consent. The lower court’s checklist had effectively substituted judicial prescription for clinical judgment.⁹ The judges also noted that the Family Law Reform Act 1969 presumes 16- and 17-year-olds can consent to medical treatment.⁸

The mandatory court-involvement regime fell away, and clinical discretion was restored. The judicial review claim was dismissed.⁶

Supreme Court Refusal

Bell applied to the UK Supreme Court, arguing the Court of Appeal had misread Gillick. On 5 May 2022 the Supreme Court refused permission, stating the application “raised no arguable point of law.”¹⁰ That ended the litigation.

What Changed Anyway: The Cass Review and the Closure of GIDS

Bell lost the legal question, but the concerns her case surfaced did not go away. NHS England had already commissioned an independent review of youth gender services in 2020, led by paediatrician Dr. Hilary Cass. Referrals to GIDS had risen from 138 in 2010–11 to 2,383 in 2020–21, the Care Quality Commission had rated the clinic “inadequate,” and whistleblowers had raised alarms about its practices.¹¹

Cass’s interim findings in 2022 concluded that a single-provider model was “not a safe or viable long-term option.” NHS England announced it would close GIDS and replace it with regional services in specialist children’s hospitals. The Tavistock clinic officially closed on 31 March 2024.¹²

The final Cass Review, published on 10 April 2024, described the evidence supporting puberty blockers and cross-sex hormones for minors as “remarkably weak.”¹³ It recommended that puberty blockers only be prescribed within a clinical trial, that services adopt a psychosocial and psychological approach as the primary model of care, and that holistic assessments screen for co-occurring conditions such as autism and mental health difficulties.¹⁴

Current UK Policy on Puberty Blockers

NHS England stopped the routine prescription of puberty-suppressing hormones for under-18s in March 2024. In December 2024 the UK government made the ban on the sale and supply of puberty blockers to under-18s for gender dysphoria indefinite, covering NHS prescriptions, private prescriptions, and prescribers registered in the UK, the European Economic Area, and Switzerland. The ban is subject to review in 2027. Existing patients already on the medication may continue treatment.¹⁵

Cross-sex hormones are not covered by the same statutory ban. The Cass Review recommended “extreme caution” and a strong clinical rationale for anyone under 18, with every case discussed by a national multi-disciplinary team.¹⁶ In March 2026 NHS England began consulting on whether to stop routinely prescribing gender-affirming hormones to children and young people at all.¹⁷

Influence Beyond the UK

Bell v Tavistock has been cited internationally as a catalyst for the shift toward restricting hormonal interventions in minors. An amicus brief filed in the US Supreme Court case United States v. Skrmetti traced a line from the 2020 challenge through the Cass Review to policy changes elsewhere. Sweden restricted puberty blockers and cross-sex hormones for minors to “exceptional cases” and research settings. Finland mandated psychosocial support as first-line treatment and limited hormonal interventions to case-by-case assessments in centralized clinics. In France, the Académie Nationale de Médecine issued a report on gender identity in minors, and the Senate considered legislation to regulate medical interventions for gender-questioning children.¹⁸

1
Transparency Project. Bell v Tavistock in the High Court: An Explainer
2
Persuasion. Keira Bell: My Story
3
Woman’s Place UK. Keira Bell: There Was Nothing Wrong With My Body
4
Mental Health Law. Bell v Tavistock and Portman NHS Foundation Trust (2021) EWCA Civ 1363
5
UK Judiciary. Bell v Tavistock Judgment
6
UK Judiciary. Bell v Tavistock Appeal Summary
7
Goodman Ray. Case Comment: R (Quincy Bell) v The Tavistock and Portman NHS Foundation Trust
8
UK Judiciary. Bell v Tavistock Court of Appeal Judgment
9
Mental Capacity Law and Policy. Gillick Competence, Puberty Blockers and the Court of Appeal
10
Mills and Reeve. Gillick Competence, Puberty Blockers and the Supreme Court
11
The Guardian. NHS Closing Down London Gender Identity Clinic for Children
12
NHS England. Children and Young People’s Gender Services: Referral Pathway Consultation Guide
13
BBC News. Cass Review: Evidence for Gender Treatments Weak
14
NHS England. Implementing the Cass Review Recommendations
15
UK Government. Ban on Puberty Blockers To Be Made Indefinite on Experts’ Advice
16
UK Government. Puberty Blockers: What You Need to Know
17
UK Parliament. Gender Identity Services for Children
18
US Supreme Court. International Groups Amicus Brief, United States v. Skrmetti